Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression

Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression

This paper presents a single-institution experience regarding the clinicopathologic features and treatment strategies used in uterine clear cell cancer (UCC), a rare, aggressive histologic subtype of uterine cancer with poor prognosis and discusses parameters associated with progression-free surviva...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Oncology 2011-01, Vol.2011 (2011), p.44-49
Hauptverfasser: Varughese, Joyce, Hui, Pei, Lu, Lingeng, Yu, Herbert, Schwartz, Peter E.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 49
container_issue 2011
container_start_page 44
container_title Journal of Oncology
container_volume 2011
creator Varughese, Joyce
Hui, Pei
Lu, Lingeng
Yu, Herbert
Schwartz, Peter E.
description This paper presents a single-institution experience regarding the clinicopathologic features and treatment strategies used in uterine clear cell cancer (UCC), a rare, aggressive histologic subtype of uterine cancer with poor prognosis and discusses parameters associated with progression-free survival (PFS) and overall survival (OS). A retrospective chart review was performed on all patients (n=80) diagnosed with UCC and treated between 1994 and 2009 at a single academic institution. Data on demographics, FIGO stage, treatment regimens, and recurrences were collected. Patients with early-stage UCC had an excellent survival regardless of adjuvant therapy. Advanced-stage patients had a worse survival. Vaginal apex brachytherapy was associated with an increased OS (P=0.02) but not PFS (P=0.10). The use of platinum-based chemotherapy in combination with vaginal apex brachytherapy did not significantly improve survival. Innovative therapies still need to be identified for this uncommon uterine cancer.
doi_str_mv 10.1155/2011/628084
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3236522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><airiti_id>P20151203007_201112_201702210005_201702210005_44_49</airiti_id><sourcerecordid>912426781</sourcerecordid><originalsourceid>FETCH-LOGICAL-a504t-9d150a551b1f0c87a208caccbfa5f26c787f017242e8110cb789cacd99542c4c3</originalsourceid><addsrcrecordid>eNqFkc1v1DAQxSMEoqVw4gzyDQm0dOzYscMBqQrfqsQetmdr1pnsusrGWzsBceB_x0vKqj1x8sf7zZvRvKJ4zuEt50qdC-D8vBIGjHxQnPLK6IWRCh7euZ8UT1K6Bqgk1NXj4kQIbrRS8rT43fSEkTXU96zBwVFkoWPjltjVSNEPxJoQ91N6x1b57yKl4DyOPgwHrOn94F3Y47gNfdh4x5YYcUe5MjEcWraKhOOOhpHlgg8-ESZiyxg2kVLKJk-LRx32iZ7dnmfF1aePq-bL4vL756_NxeUCFchxUbdcASrF17wDZzQKMA6dW3eoOlE5bXQHXAspyHAObq1NnfW2rpUUTrryrHg_--6n9Y5alyeK2Nt99DuMv2xAb-8rg9_aTfhhS1FWSohs8OrWIIabidJodz65vDQcKEzJ1jw3r7ThmXwzky6GlCJ1xy4c7CEve8jLznll-uXdwY7sv4Ay8HoGtn5o8af_j9uLGaaMUIdHWJqqlCrr32YdffSjt9dhikPeu11mF8UFlAD6ryMXh0NDngMA1P2HlFbW5R-J47zS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>912426781</pqid></control><display><type>article</type><title>Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression</title><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Varughese, Joyce ; Hui, Pei ; Lu, Lingeng ; Yu, Herbert ; Schwartz, Peter E.</creator><contributor>Penson, Richard T.</contributor><creatorcontrib>Varughese, Joyce ; Hui, Pei ; Lu, Lingeng ; Yu, Herbert ; Schwartz, Peter E. ; Penson, Richard T.</creatorcontrib><description>This paper presents a single-institution experience regarding the clinicopathologic features and treatment strategies used in uterine clear cell cancer (UCC), a rare, aggressive histologic subtype of uterine cancer with poor prognosis and discusses parameters associated with progression-free survival (PFS) and overall survival (OS). A retrospective chart review was performed on all patients (n=80) diagnosed with UCC and treated between 1994 and 2009 at a single academic institution. Data on demographics, FIGO stage, treatment regimens, and recurrences were collected. Patients with early-stage UCC had an excellent survival regardless of adjuvant therapy. Advanced-stage patients had a worse survival. Vaginal apex brachytherapy was associated with an increased OS (P=0.02) but not PFS (P=0.10). The use of platinum-based chemotherapy in combination with vaginal apex brachytherapy did not significantly improve survival. Innovative therapies still need to be identified for this uncommon uterine cancer.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2011/628084</identifier><identifier>PMID: 22187554</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><ispartof>Journal of Oncology, 2011-01, Vol.2011 (2011), p.44-49</ispartof><rights>Copyright © 2011 Joyce Varughese et al.</rights><rights>Copyright © 2011 Joyce Varughese et al. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a504t-9d150a551b1f0c87a208caccbfa5f26c787f017242e8110cb789cacd99542c4c3</citedby><cites>FETCH-LOGICAL-a504t-9d150a551b1f0c87a208caccbfa5f26c787f017242e8110cb789cacd99542c4c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236522/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236522/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22187554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Penson, Richard T.</contributor><creatorcontrib>Varughese, Joyce</creatorcontrib><creatorcontrib>Hui, Pei</creatorcontrib><creatorcontrib>Lu, Lingeng</creatorcontrib><creatorcontrib>Yu, Herbert</creatorcontrib><creatorcontrib>Schwartz, Peter E.</creatorcontrib><title>Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression</title><title>Journal of Oncology</title><addtitle>J Oncol</addtitle><description>This paper presents a single-institution experience regarding the clinicopathologic features and treatment strategies used in uterine clear cell cancer (UCC), a rare, aggressive histologic subtype of uterine cancer with poor prognosis and discusses parameters associated with progression-free survival (PFS) and overall survival (OS). A retrospective chart review was performed on all patients (n=80) diagnosed with UCC and treated between 1994 and 2009 at a single academic institution. Data on demographics, FIGO stage, treatment regimens, and recurrences were collected. Patients with early-stage UCC had an excellent survival regardless of adjuvant therapy. Advanced-stage patients had a worse survival. Vaginal apex brachytherapy was associated with an increased OS (P=0.02) but not PFS (P=0.10). The use of platinum-based chemotherapy in combination with vaginal apex brachytherapy did not significantly improve survival. Innovative therapies still need to be identified for this uncommon uterine cancer.</description><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><recordid>eNqFkc1v1DAQxSMEoqVw4gzyDQm0dOzYscMBqQrfqsQetmdr1pnsusrGWzsBceB_x0vKqj1x8sf7zZvRvKJ4zuEt50qdC-D8vBIGjHxQnPLK6IWRCh7euZ8UT1K6Bqgk1NXj4kQIbrRS8rT43fSEkTXU96zBwVFkoWPjltjVSNEPxJoQ91N6x1b57yKl4DyOPgwHrOn94F3Y47gNfdh4x5YYcUe5MjEcWraKhOOOhpHlgg8-ESZiyxg2kVLKJk-LRx32iZ7dnmfF1aePq-bL4vL756_NxeUCFchxUbdcASrF17wDZzQKMA6dW3eoOlE5bXQHXAspyHAObq1NnfW2rpUUTrryrHg_--6n9Y5alyeK2Nt99DuMv2xAb-8rg9_aTfhhS1FWSohs8OrWIIabidJodz65vDQcKEzJ1jw3r7ThmXwzky6GlCJ1xy4c7CEve8jLznll-uXdwY7sv4Ay8HoGtn5o8af_j9uLGaaMUIdHWJqqlCrr32YdffSjt9dhikPeu11mF8UFlAD6ryMXh0NDngMA1P2HlFbW5R-J47zS</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Varughese, Joyce</creator><creator>Hui, Pei</creator><creator>Lu, Lingeng</creator><creator>Yu, Herbert</creator><creator>Schwartz, Peter E.</creator><general>Hindawi Limiteds</general><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110101</creationdate><title>Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression</title><author>Varughese, Joyce ; Hui, Pei ; Lu, Lingeng ; Yu, Herbert ; Schwartz, Peter E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a504t-9d150a551b1f0c87a208caccbfa5f26c787f017242e8110cb789cacd99542c4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Varughese, Joyce</creatorcontrib><creatorcontrib>Hui, Pei</creatorcontrib><creatorcontrib>Lu, Lingeng</creatorcontrib><creatorcontrib>Yu, Herbert</creatorcontrib><creatorcontrib>Schwartz, Peter E.</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Varughese, Joyce</au><au>Hui, Pei</au><au>Lu, Lingeng</au><au>Yu, Herbert</au><au>Schwartz, Peter E.</au><au>Penson, Richard T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression</atitle><jtitle>Journal of Oncology</jtitle><addtitle>J Oncol</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>2011</volume><issue>2011</issue><spage>44</spage><epage>49</epage><pages>44-49</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>This paper presents a single-institution experience regarding the clinicopathologic features and treatment strategies used in uterine clear cell cancer (UCC), a rare, aggressive histologic subtype of uterine cancer with poor prognosis and discusses parameters associated with progression-free survival (PFS) and overall survival (OS). A retrospective chart review was performed on all patients (n=80) diagnosed with UCC and treated between 1994 and 2009 at a single academic institution. Data on demographics, FIGO stage, treatment regimens, and recurrences were collected. Patients with early-stage UCC had an excellent survival regardless of adjuvant therapy. Advanced-stage patients had a worse survival. Vaginal apex brachytherapy was associated with an increased OS (P=0.02) but not PFS (P=0.10). The use of platinum-based chemotherapy in combination with vaginal apex brachytherapy did not significantly improve survival. Innovative therapies still need to be identified for this uncommon uterine cancer.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>22187554</pmid><doi>10.1155/2011/628084</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-8450
ispartof Journal of Oncology, 2011-01, Vol.2011 (2011), p.44-49
issn 1687-8450
1687-8450
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3236522
source Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access
title Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T15%3A16%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clear%20Cell%20Cancer%20of%20the%20Uterine%20Corpus:%20The%20Association%20of%20Clinicopathologic%20Parameters%20and%20Treatment%20on%20Disease%20Progression&rft.jtitle=Journal%20of%20Oncology&rft.au=Varughese,%20Joyce&rft.date=2011-01-01&rft.volume=2011&rft.issue=2011&rft.spage=44&rft.epage=49&rft.pages=44-49&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2011/628084&rft_dat=%3Cproquest_pubme%3E912426781%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=912426781&rft_id=info:pmid/22187554&rft_airiti_id=P20151203007_201112_201702210005_201702210005_44_49&rfr_iscdi=true